Workflow
宁科生物(600165) - 2021 Q1 - 季度财报
NSWRCNSWRC(SH:600165)2021-04-29 16:00

Financial Performance - Operating revenue increased by 83.43% to CNY 38,258,881.35 year-on-year[6] - Net profit attributable to shareholders rose by 81.25% to CNY 2,769,519.22 compared to the same period last year[6] - Basic earnings per share increased by 81.82% to CNY 0.0040 per share[6] - The weighted average return on net assets increased by 70.44 percentage points to 28.92%[6] - Total operating revenue for Q1 2021 was ¥38,258,881.35, a 83.5% increase from ¥20,857,657.03 in Q1 2020[30] - Net profit for Q1 2021 was ¥555,689.94, a decrease of 54.2% compared to ¥1,214,241.21 in Q1 2020[30] - The company reported a profit attributable to shareholders of ¥2,769,519.22 in Q1 2021, compared to ¥1,528,035.07 in Q1 2020[31] - The total comprehensive income for Q1 2021 was CNY 7,836,750.95, up from CNY 6,012,921.32 in Q1 2020, reflecting a growth of approximately 30.3%[36] Cash Flow - Net cash flow from operating activities improved significantly to CNY 3,876,689.24, compared to a negative CNY 9,204,499.83 in the previous year[6] - The net cash flow from operating activities was CNY 3,876,689.24, a turnaround from a negative cash flow of CNY -9,204,499.83 in the same period last year[39] - Investment activities generated a net cash flow of CNY 100,133,141.46 in Q1 2021, a significant improvement from a negative cash flow of CNY -93,421,084.64 in the previous year[40] - The net cash flow from financing activities was CNY 1,793,004.67, down from CNY 2,182,019.49 in Q1 2020[42] Assets and Liabilities - Total assets decreased by 3.96% to CNY 3,202,558,849.44 compared to the end of the previous year[6] - The company's current assets totaled CNY 501,382,750.68, down from CNY 719,321,307.10, indicating a decrease of about 30.39%[22] - Total liabilities decreased to CNY 1,928,894,270.26 from CNY 2,061,673,621.86, a reduction of approximately 6.43%[24] - Total assets as of the end of Q1 2021 were ¥1,682,406,322.12, compared to ¥1,669,657,760.03 at the end of Q1 2020[28] - Total liabilities as of the end of Q1 2021 were ¥666,051,798.88, an increase from ¥661,139,987.74 at the end of Q1 2020[28] Shareholder Information - The number of shareholders at the end of the reporting period was 34,240[8] - The largest shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., holds 29.20% of the shares[8] Operating Costs - Operating costs increased by 59.21% to ¥33,413,521.76, also due to the inclusion of Ningxia Tianfu in the consolidated financial statements.[14] - Total operating costs for Q1 2021 were ¥50,307,982.35, up 48.1% from ¥33,995,143.04 in Q1 2020[30] Other Financial Metrics - Government subsidies recognized in the current period amounted to CNY 165,053.31[6] - The company reported a total of CNY 61,365.36 in non-recurring gains and losses[8] - Research and development expenses for Q1 2021 were ¥787,790.48, significantly higher than ¥220,952.96 in Q1 2020[30] - The company incurred financial expenses of CNY 3,176,465.29 in Q1 2021, down from CNY 4,131,426.19 in Q1 2020, showing a reduction of approximately 23.1%[34] Inventory and Receivables - Accounts receivable decreased by 39.00% to ¥27,797,255.86, mainly due to the recovery of payments by subsidiary Ningxia Huahui Environmental Technology Co., Ltd.[13] - The company's inventory increased to CNY 84,403,632.16 from CNY 79,610,182.22, reflecting a growth of about 6.98%[22] Investments and Projects - The company is in the trial production phase for the 50,000 tons/year lauric acid project, with stable operation and qualified product quality.[17] - The company has completed all property rights procedures for the purchase of the Golden Water Talent Apartment project, with a total purchase amount of ¥134,387,479.00.[17]